Lv1
70 积分 2025-09-09 加入
Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma
26天前
已完结
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
26天前
已完结
Genomic correlates of clinical CAR T cell activity
28天前
已完结
Ultralow-Dose Interleukin 10-Expressing Chimeric Antigen Receptor T Cells in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Nonrandomized Clinical Trial
28天前
已完结
Simultaneous auto-transplant and CD19 CAR T-cell 2nd line therapy followed by CD20 × CD3 bispecific antibody for refractory Burkitt lymphoma, a case report
1个月前
已完结
Early Recognition of ICANS with a NoveI EEG-Based Delta Wave Detection System in Patients Receiving CAR T-cell Therapy
2个月前
已关闭
Early Recognition of ICANS with a NoveI EEG.Based Delta Wave Detection System inPatients Receiving CAR T-cell Therapy
2个月前
已关闭
Comparative Analysis of Lymphodepletion Regimens in CART-19 Treatment for Relapsed/Refractory Diffuse Large B Cell Lymphoma
3个月前
已完结
Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial
3个月前
已完结
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
3个月前
已完结
皖公网安备34019202002308
